[
    {
        "pathogenId": 1,
        "name": "Respiratory Syncytial Virus (RSV)",
        "description": "Respiratory Syncytial Virus (RSV) is a common respiratory virus that causes infections in the lungs and respiratory tract. It is known for causing cold-like symptoms, but it can lead to more severe respiratory illnesses, such as bronchiolitis and pneumonia, particularly in young children and older adults. RSV is highly contagious and spreads through respiratory droplets, making it a significant concern during the winter months.",
        "vaccines": [
            {
                "vaccineId": 1
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/489/course/overviewfiles/Picture1.png",
        "bulletpoints": "The respiratory syncytial virus (RSV) is an RNA virus that causes annual ARI outbreaks during winter with mild URTI in the general population, but with severe LRTI particularly among young children (bronchiolitis), patients with underlying diseases and people >65 years of age.|RSV does not induce a long-lasting protective immunity and repeated infections throughout life are the norm.|Basically, all children have been infected by 2 years of age and of those hospitalized, >50% are <3 months and 75% are <6 months of age. The overall CFR is 1/500.|For adults ≥65 years, RSV hospitalization rates are 90–250/105.|There is no specific therapy, general preventive measures include general hygiene and isolation/separation of patients.|A monoclonal anti-F-protein antibody is available for passive immunization of selected high-risk children. It requires monthly injections, comes at a high cost and has limited efficacy (50% against RSV hospitalization).|Active immunization failed in the past, probably as the post-fusion conformation of the F-protein was used.|Long-acting monoclonal antibodies (for infants) as well as stabilized pre-fusion F-protein vaccines (for immunization of pregnant women, children, older adults) produced on various platforms are in late stages of clinical development.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=RSV"
    },
    {
        "pathogenId": 2,
        "name": "SARS-CoV-2",
        "description": "COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus. It was first identified in Wuhan, China, in late 2019 and has since become a global pandemic. Symptoms can range from mild, such as fever and cough, to severe, including difficulty breathing and pneumonia. The virus primarily spreads through respiratory droplets and can lead to significant health complications, particularly in older adults and those with underlying health conditions.",
        "vaccines": [
            {
                "vaccineId": 4
            },
            {
                "vaccineId": 9
            },
            {
                "vaccineId": 10
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/555/course/overviewfiles/44%20-%20COVID19%20small.png",
        "bulletpoints": "Coronavirus disease 19 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus which emerged in Wuhan, China in 2019, and from there spread to other parts of mainland China and around the world.|The virus spreads mainly through respiratory droplets produced when an infected person coughs, sneezes, or speaks. On average, the time from exposure to SARS-CoV-2 to the appearance of symptoms is 5–6 days but can range from 1–14 days.|Asymptomatic infections with SARS-CoV-2 can occur. In those with symptoms, most people (approx. 80%) will experience a mild to moderate respiratory illness and recover without hospital management.|Adults 65 years of age and older, and individuals of any age with underlying medical conditions, are at increased risk for severe COVID-19 and death. Complications include respiratory failure, acute respiratory distress syndrome, sepsis/septic shock, thromboembolism, multiorgan failure and death.|In rare cases, children and adults can develop a severe inflammatory syndrome a few weeks after SARS-CoV-2 infection.|Vaccines are available to help prevent COVID-19 disease; by August 2021,7 vaccines had been authorized for use by the WHO to prevent COVID-19 caused by SARS-CoV-2, with others approved by country regulatory authorities. For regular updates, please see VacciPROFILES.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=SARS"
    },
    {
        "pathogenId": 3,
        "name": "Streptococcus pneumoniae",
        "description": "Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae. It can lead to various serious infections, including pneumonia, meningitis, and sepsis. The disease predominantly affects children and older adults, but can also impact other age groups. Symptoms can range from mild respiratory issues to severe illness requiring hospitalization.",
        "vaccines": [
            {
                "vaccineId": 3
            },
            {
                "vaccineId": 5
            },
            {
                "vaccineId": 6
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/543/course/overviewfiles/34%20-%20Streptococcus%20pneumoniae%20small.png",
        "bulletpoints": "Streptococcus pneumoniae is a Gram-positive encapsulated diplococcus. |The capsule determines the ≥100 serotypes, is the relevant vaccine antigen and the main pathogenicity factor.  |Children <5 years are the main reservoir and often spread S. pneumoniae to the elderly.|Presence of an acute viral respiratory tract infection (ARI) may favor the development of mucosal pneumococcal infections, as theoretical, experimental, epidemiological, and clinical data indicate viral-bacterial synergy.|Many risk factors like anatomical and immunological factors, underlying diseases, and environmental/behavioral factors favor development of invasive pneumococcal disease (IPD).|Pneumococcal diseases can be treated with different groups of antibiotics, depending on the local resistance situation.|Polysaccharide and polysaccharide-conjugate vaccines are used for pneumococcal disease prevention.|The disadvantages of 23-valent pneumococcal polysaccharide vaccine (Pneumovax®) are lack of memory cell induction, and thus no booster response,no reduction of carriage, and thus no herd protection,lack of IgG immune response in children <2 years,only short-term and moderate protection rates in subjects ≥65 years against bacteremic pneumonia only.In contrast, pneumococcal conjugate vaccines (PCVs) generate a memory response in all ages,can reduce pneumococcal acquisition/colonization,reduce mucosal diseases (otitis media, non-bacteremic pneumonia, IPD),and there is long-term protection.|Currently licensed and marketed PCVs are PCV10 (Synflorix®, not licensed in the USA; indicated only for children), PCV13 (Prevenar 13® [Europe]; Prevnar 13® [USA]) and PCV15 (Vaxneuvance®) which are both licensed in EU and USA for adults and children, and PCV20 (Prevnar 20® [USA]; Apexxnar® [Europe]) which is currently only licensed for use in adults.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Streptococcus"
    },
    {
        "pathogenId": 4,
        "name": "Tick-Borne Encephalitis (TBE)",
        "description": "Tick-borne encephalitis (TBE) is a viral infection transmitted by ticks that affects the central nervous system. It can cause severe symptoms including encephalitis, meningitis, and can lead to long-term neurological problems. The vaccine is recommended for individuals living in or traveling to areas where TBE is prevalent.",
        "vaccines": [
            {
                "vaccineId": 7
            },
            {
                "vaccineId": 12
            },
            {
                "vaccineId": 13
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/523/course/overviewfiles/51%20-%20Tick%20Borne%20Encephalitis%20b.png",
        "bulletpoints": "Tick-borne encephalitis (TBE) is the medically most common tick-borne viral disease in Europe and Asia.|The TBE virus (TBEV) is a member of the family Flaviviridae.|Transmission mainly to humans occurs by ticks of the Family Ixodidae, mainly the castor bean tick (Ixodes ricinus) in Europe and the taiga tick (Ixodes persulcatus) in Asia. Rarely TBEV is also transmitted by contaminated milk of infected ungulates (goat, sheep, cow).|The clinical course of TBE is variable and may range from subclinical to fatal encephalomyelitis. Probably host and viral factors are involved in the pathogenesis of disease.|So far, no specific treatment of the disease is available.|The only effective prevention of TBE is vaccination. A number of different vaccines are available worldwide. In Europe two vaccines are licensed which contain inactivated European subtype TBEV.|Probably the European vaccines protect also against infections with other subtypes of TBEV.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=TBE"
    },
    {
        "pathogenId": 5,
        "name": "Neisseria meningitidis",
        "description": "Neisseria meningitidis, often referred to as the meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. ",
        "vaccines": [
            {
                "vaccineId": 8
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/541/course/overviewfiles/35%20-%20Neisseria-meningitidis-diseases%20small.png",
        "bulletpoints": "Meningococcal disease is caused by the Gram-negative bacterium Neisseria meningitidis (the meningococcus). It remains a significant public health issue globally causing both endemic and epidemic disease in developed and developing countries.|Approximately 10% of humans harmlessly carry N. meningitidis in the oronasopharynx. On very rare occasions the bacteria may cross the epithelium and enter the blood stream causing sudden onset of sepsis and or meningitis with high complication and case fatality rates, even with appropriate antibiotic treatment.|A limited number of strains cause the majority of invasive disease and, in normally healthy individuals, these practically always express a protective polysaccharide capsule on their cell surface.|There are 12 capsular serogroups, of which A, B, C, W, X and Y cause the vast majority of invasive meningococcal disease worldwide.|Polysaccharide-based vaccines target the capsule and so are serogroup-specific.|Plain (unconjugated) polysaccharide vaccines were developed first and have been used in control of serogroup A epidemics in sub-Saharan Africa and for controlling serogroup C disease in the military and college students. Associated limitations include poor immunogenicity in young children, hyporesponsiveness with repeat doses, inability to induce immune memory and lack of an effect on carriage.|Conjugated polysaccharide vaccines have none of these limitations and, most importantly, significantly reduce carriage. Therefore, large scale vaccination of cohorts with high carriage (catch-up campaigns) are highly effective in inducing herd protection.|Serogroup C conjugate vaccines have been hugely successful in dramatically reducing disease in the countries that have instigated immunization programs together with appropriate catch-up campaigns.|Meningococcal quadrivalent conjugate vaccines are now being implemented into schedules.|With the development and introduction of a meningococcal serogroup A conjugate vaccine, serogroup A disease has disappeared from those sub-Saharan countries who have implemented campaigns. |The serogroup B polysaccharide is poorly immunogenic and so broad coverage protein-based serogroup B vaccines have been developed.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Neisseria"
    },
    {
        "pathogenId": 6,
        "name": "Human Papilloma Virus (HPV)",
        "description": "Human papillomavirus (HPV) is a viral infection that commonly causes skin or mucous membrane growths (warts).",
        "vaccines": [
            {
                "vaccineId": 11
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/507/course/overviewfiles/45%20-%20Human%20Papillomavirus%20diseases%20small.png",
        "bulletpoints": "HPV is extremely common worldwide and mainly transmitted through sexual contact; most people are infected with HPV shortly after onset of sexual activity.|There are >200 types of HPV, of which at least 12 are cancer-causing (oncogenic or high-risk types). |HPV is a causal factor for several anogenital and a subset of oropharyngeal cancers with 2 HPV types (16 and 18) causing 72% of all HPV-associated cancers. |Cervical cancer is the fourth most common cancer among women globally with nearly 90% of the deaths occurring in low- and middle-income countries. |Comprehensive cervical cancer control includes primary prevention (vaccination against HPV), secondary prevention (screening and treatment of pre-cancerous lesions) as well as treatment of invasive cervical cancer. |The currently licensed vaccines are L1 VLP-based and prophylactic; they have been shown to be safe and highly effective in preventing HPV infections and HPV-associated lesions, precancer and cancer. |Neutralizing antibodies are the mechanism of protection for prophylactic HPV VLP-based vaccines.|Therapeutic HPV vaccines targeting the oncoproteins E6 and E7 are in clinical development.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=HPV"
    },
    {
        "pathogenId": 7,
        "name": "Chikungunya Virus",
        "vaccines": [
            {
                "vaccineId": 25
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/491/course/overviewfiles/59%20-%20Chikungunya.png",
        "bulletpoints": "Chikungunya is a viral disease with fever, severe joint pain and rash transmitted by infected Aedes mosquitoes.|The virus was first isolated in Tanzania in 1952 and has since spread around the globe with major outbreaks in the Indian Ocean islands in 2005-2006 and the Americas in 2013-2014.|Chikungunya can lead to chronic joint pain lasting months or years in 30-40% of cases, especially in those with pre-existing joint diseases.|There is no specific antiviral treatment, and management focuses on symptom relief with rest, fluids, and pain medications.|Prevention relies on mosquito control measures and personal protection to avoid mosquito bites in areas with chikungunya transmission.|The first chikungunya vaccine, Ixchiq is a live attenuated vaccine, It was approved by the FDA in November 2023 as a single dose for individuals 18 years of age and older at high risk of exposure. Ixchiq owns a good safety profile with acceptable tolerability. It induces high levels of neutralizing antibodies in vaccinated individuals. Several other vaccine candidates are under development.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Chikungunya"
    },
    {
        "pathogenId": 8,
        "name": "Influenza Virus",
        "description": "Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to hospitalization or death. It is spread mainly through respiratory droplets.",
        "vaccines": [
            {
                "vaccineId": 15
            },
            {
                "vaccineId": 22
            },
            {
                "vaccineId": 28
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/525/course/overviewfiles/43%20-%20Influenza.png",
        "bulletpoints": "The influenza virus is a segmented RNA virus with different mechanisms for mutations, and hence for minor (antigenic drift) and major (antigenic shift) changes.|Influenza virus A was responsible for pandemics on average every 30 years in the past, with the most recent being the 2009 swine-origin influenza A H1N1 (SO-H1N1). |The clinical picture is unspecific: seasonal or pandemic influenza cannot be differentiated from other viral respiratory infections on clinical grounds. PCR has become the standard for microbiological confirmation of the diagnosis. |Treatment options remain limited with neuraminidase inhibitors (oseltamivir; zanamivir). Resistance may occur under treatment or under prophylaxis; however, it is still rare overall. |Vaccination is still the preferred method for prevention. However, the long lead time for production (at least 6 months) poses a challenge. Innovative new techniques like cell culture or recombinant productions are urgently needed. |Pandemic influenza vaccines for SO-H1N1 were shown to be effective and safe in children, pregnant women, adults, and also in elderly",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=influenza"
    },
    {
        "pathogenId": 9,
        "name": "Hepatitis B Virus",
        "description": "Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic diseases. It is spread through contact with infectious body fluids.",
        "vaccines": [
            {
                "vaccineId": 15
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/537/course/overviewfiles/37%20-%20Hepatitis%20B%20small.png",
        "bulletpoints": "HBV disease is a significant cause of acute and chronic liver disease worldwide.|Mother-to-infant transmission is the main mode of transmission to susceptible subjects, which can be prevented with HBV vaccine alone or in combination with hepatitis B immunoglobulin. This intervention markedly reduces the number of new HBsAg carriers.|For subjects not responding to current HBV vaccines as reflected by an inadequate anti-HBs titer, future generation vaccines incorporating additional vaccine components such as preS1 and preS2 may improve the efficacy of protective antibody production.|Apart from preventative vaccines, future therapeutic vaccines along with current anti-HBV treatment strategies might enhance the rate of functional cures as indicated by the loss of HBsAg.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Hepatitis"
    },
    {
        "pathogenId": 10,
        "name": "Hepatitis A Virus",
        "description": "Hepatitis A is a highly contagious liver infection caused by the hepatitis A virus. It is transmitted through consumption of contaminated food and water.",
        "vaccines": [
            {
                "vaccineId": 27
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/539/course/overviewfiles/36%20-%20Hepatitis%20A%20small.png",
        "bulletpoints": "Hepatitis A virus (HAV) is a single-stranded “nonenveloped” RNA virus in the picornaviridae family.|HAV is most often transmitted by the fecal-oral route, but also by contaminated food, water, sexual contact, and intravenous drug use.|HAV causes little if any symptoms in the very young.|Disease symptoms from liver damage become more frequent in older ages and even fulminant liver failure with death is observed in the elderly.|Unlike hepatitis B and C, hepatitis A does not cause chronic liver disease.|With lack of sanitation and hygiene, HAV infection occurs early in life inducing life-long protection, whereas in countries with good sanitation and hygiene, infections are seen later in life and are more severe. |There is no causal treatment, but available vaccines are well tolerated, have an excellent safety profile and are highly effective with long-lasting protection after 2 doses.|Hepatitis A vaccines can be used for pre- as well as for post-exposure prophylaxis and for individual as well as for population protection.|Vaccinating a small fraction of the population (3%) – i.e., children aged 1–4 years serving as the reservoir and source of HAV – resulted in herd protection with 96% disease reduction in the whole population of Israel.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Hepatitis"
    },
    {
        "pathogenId": 11,
        "name": "Varicella-Zoster Virus (VZV)",
        "description": "Varicella-zoster virus (VZV) causes chickenpox and shingles. Chickenpox is a highly contagious disease characterized by an itchy rash and flu-like symptoms. Shingles is a painful rash that occurs later in life due to the reactivation of VZV.",
        "vaccines": [
            {
                "vaccineId": 17
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/529/course/overviewfiles/41%20-%20Varicella-Zoster%20small.png",
        "bulletpoints": "A live attenuated vaccine against varicella (later also used to prevent zoster) was developed in 1974 by Takahashi and colleagues.|Varicella vaccine was licensed for universal immunization of healthy children in the United States in 1995. It is also now used for this purpose in at least 15 additional countries all over the world. Varicella is disappearing in the US.|Varicella vaccine has proven extremely safe and side effects are unusual, mild, and less serious than varicella or its complications.|85% of children are protected completely after 1 dose; the 15% who develop varicella despite immunization usually (but not always) have mild infections. These 15%, however, can transmit the wild type virus to others.|Therefore, for optimal effect, 2 doses are required, mostly to address children who did not have an optimal primary immune response after the first dose.|Waning immunity does not seem to pose a serious problem, but surveillance of vaccinees is continuing.|It was demonstrated in 2005 that at a high dose of vaccine – 15 times higher than that used for prevention of varicella in children – zoster in adults can also be safely prevented.|The live attenuated zoster vaccine is effective in approximately 50% of healthy individuals over age 60 who have had varicella in the past, and therefore have latent infection with varicella-zoster virus. It is given as one dose, but its effect runs out about 8 years after vaccination.In 2017, a new vaccine against zoster was also introduced. This is a subunit vaccine which does not contain contagious virus. It is even more effective than the older zoster vaccine and is over 95% effective in adults 50–≥70 years of age in preventing zoster and post herpetic neuralgia.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Varicella"
    },
    {
        "pathogenId": 12,
        "name": "Measles Virus",
        "description": "Measles is a highly contagious viral disease characterized by a rash, fever, and cough. It can lead to severe complications, including pneumonia and encephalitis.",
        "vaccines": [
            {
                "vaccineId": 18
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/535/course/overviewfiles/38%20-%20Measles%20small.png",
        "bulletpoints": "Measles, known from the early ages, is caused by a paramyxovirus.|A Persian colleague named Rhazes (854–925 A.D.) was likely the first to distinguish smallpox from measles, this milder disease getting the name “morbilli” (little disease) from the Latin word morbus (disease).|Being one of the most contagious infections, a measles-infected individual may on average transmit the virus to 12–18 susceptible persons from 3–4 days before to soon after first clinical symptoms appear.|Essentially only mankind’s (and some monkey species’) disease, measles is potentially eradicable by vaccination, provided vaccine uptake exceeds 95% for a long enough time. This remains a challenge, and we likely will continue to have measles with us for a long time. ",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Measles"
    },
    {
        "pathogenId": 13,
        "name": "Mumps Virus",
        "description": "Mumps is a contagious disease caused by the mumps virus, leading to swollen salivary glands, fever, and headache. It can lead to complications such as meningitis and orchitis.",
        "vaccines": [
            {
                "vaccineId": 19
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/531/course/overviewfiles/40%20-%20Mumps%20small.png",
        "bulletpoints": "Like measles, mumps is caused by a paramyxovirus, and it is only a disease of humans. The word 'mumps' may relate to an old English term meaning grimace or mumble.|Mumps was first described by Hippocrates (460-377 B.C.) in his book “Epidemics”, where he noted the presence of swelling around the ears and painful swelling of the testes. Central nervous system involvement was published by R Hamilton in 1790 in Scotland.|Being less contagious than measles, an infected individual may still transmit mumps to 10-12 susceptible persons from 3-4 days before onset until 2 days after the onset of symptoms.|Several live virus strains were developed as vaccine strains. Jeryl Lynn and its derivative RIT-4385 are in wide use in industrialized countries, L-Zagreb in the non-industrialized world.|As the interpretation of serological data is not well understood the clinical value of mumps vaccines is evaluated on the basis of impact data only.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=mumps"
    },
    {
        "pathogenId": 14,
        "name": "Rubella Virus",
        "description": "Rubella, also known as German measles, is a viral infection characterized by a rash and fever. It can cause severe birth defects if contracted by pregnant women.",
        "vaccines": [
            {
                "vaccineId": 20
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/533/course/overviewfiles/39%20-%20Rubella%20small.png",
        "bulletpoints": "Rubella is caused by an RNA virus. Infection results mostly in few or no symptoms. Viremia and viral shedding start before a rash may be seen.|German physicians were probably the first to describe rubella in the early 19th century, hence the name 'German measles'. A British physician reported an outbreak in a boys’ school in India in 1841. He used the word rubella, 'little red', a Latin diminutive from ruber (red).|Rubella is often indistinguishable from other viral exanthematous diseases, but palpable posterior auricular and suboccipital lymph nodes are almost pathognomonic.|Rubella infection during pregnancy may result in cataract, heart disease and deafness in an infant, forming the key triad defining “congenital rubella syndrome”, CRS. Also, mental retardation is common. After birth, rubella is a mild disease with rare complications only.|There is no treatment for rubella or CRS, but vaccination programs usually with MMR-vaccine maintaining high vaccine uptake over time can virtually eliminate rubella.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=rubella"
    },
    {
        "pathogenId": 15,
        "name": "Yellow Fever Virus",
        "description": "Yellow fever is a viral disease transmitted by mosquitoes, characterized by fever, chills, and muscle pain. In severe cases, it can lead to liver damage and bleeding.",
        "vaccines": [
            {
                "vaccineId": 21
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/515/course/overviewfiles/53%20-%20Yellow%20Fever%20small.png",
        "bulletpoints": "Yellow fever is an acute viral hemorrhagic disease transmitted by infected mosquitoes. The 'yellow' in the name refers to the jaundice from direct liver damage.|The virus is endemic in tropical areas of Africa and Central and South America.|There is no specific treatment or antiviral drug for yellow fever but appropriate supportive treatment in hospitals improves survival rates.|Vaccination is the single most important preventive measure. Several yellow fever vaccines are manufactured by different developers. All of them are safe, affordable, and appear to provide protection for >30–35 years. Some are WHO-prequalified.|The Eliminate Yellow Fever Epidemics (EYE) Strategy launched in 2017 aims at protecting at-risk populations, preventing international spread, and containing outbreaks rapidly. By 2026, it is expected that more than 1 billion people will be protected against the disease.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=yellow+fever"
    },
    {
        "pathogenId": 20,
        "name": "Rabies virus (RabV)",
        "description": "Rabies virus is a neurotropic virus that causes rabies, a fatal disease that affects the central nervous system. It is transmitted primarily through the bite of an infected animal. The RabAvert vaccine uses an inactivated form of the virus to provide immunity.",
        "vaccines": [
            {
                "vaccineId": 17
            },
            {
                "vaccineId": 30
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/521/course/overviewfiles/50%20-%20Rabies%20small.png",
        "bulletpoints": "Rabies is the deadliest disease known to mankind and yet it is virtually 100% vaccine preventable.|There are no known cures for rabies once clinical symptoms are evident.|Over 95% of all human deaths occur in Asia and Africa and approximately 99% of all deaths are caused by exposure to infected dogs.|Children under 15 years of age constitute an estimated 40% of the victims of rabies and they should be targeted for increased educational awareness programs.|In regions where the exposure rates are high and access to rabies vaccines is limited, administering pre-exposure-prophylaxis (PrEP) to children would save lives.|Rabies is significantly under-reported and often misdiagnosed as another encephalitic disease.|Travelers visiting rabies endemic countries where vaccine supplies are limited should consider receiving PrEP (vaccination).",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=Rabies"
    },
    {
        "pathogenId": 23,
        "name": "Japanese Encephalitis Virus (JEV)",
        "description": "Japanese Encephalitis Virus (JEV) is a mosquito-borne virus that causes Japanese encephalitis, a severe neurological disease. JEV primarily affects children and can cause inflammation of the brain, leading to symptoms like high fever, headache, neck stiffness, seizures, and, in severe cases, permanent neurological damage or death.",
        "vaccines": [
            {
                "vaccineId": 29
            }
        ],
        "image": "https://vaccitutor.com/pluginfile.php/513/course/overviewfiles/49%20-%20Japanese%20Encephalitis%20small.png",
        "bulletpoints": "Japanese Encephalitis (JE) is an endemic vector-borne (mosquitoes) zoonotic flavivirus disease in Asia with severe neurological manifestations (case fatality rate CFR 20–30%; 30–50% of survivors with serious sequelae).|Japanese Encephalitis Virus (JEV) is the leading cause of viral encephalitis in Asia and exposes an estimated 3 billion people to the risk of infection. Other regions of the world have conditions suiting JEV without circulation of the virus (yet).|Most JEV infections are asymptomatic or only cause mild symptoms. 1 in 250 infections progresses to severe disease for which no specific treatment is yet available.|Neutralizing antibodies develop after infection. In endemic areas this occurs usually during childhood followed by subclinical re-exposure with life-long immunity protecting against disease. Disease in adult populations in endemic areas is rare.|General prevention includes avoidance of mosquito bites, e.g., repellents, long-sleeved clothes, coils and vaporizers.|Vaccine prevention: Neutralizing antibodies (PRNT50 titer ≥ 1: 10) is the correlate of protection. Vaccines currently used are live attenuated JE vaccines and recombinant chimeric JE vaccines (mostly in endemic countries) and cell culture-derived inactivated JE vaccines (travelers, endemic countries).|As animal reservoirs of the JEV cannot be eradicated, universal vaccination of humans can control the disease in humans. Optimal JE control in endemic countries is limited by issues around vaccine supply, surveillance (burden of disease underestimation), and resource competition / prioritization.",
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=JEV"
    },
    {
        "pathogenId": 24,
        "name": "Norovirus",
        "description": "Norovirus is a highly contagious virus that causes gastroenteritis, leading to inflammation of the stomach and intestines. It is often associated with outbreaks of vomiting and diarrhea, especially in enclosed environments like cruise ships, hospitals, and schools. The virus is transmitted through contaminated food, water, surfaces, or from person to person. While typically mild, norovirus infections can cause severe dehydration, particularly in vulnerable populations such as young children, the elderly, and immunocompromised individuals.",
        "vaccines": [
            {}
        ],
        "link": "https://vaccitutor.com/course/search.php?areaids=core_course-course&q=norovirus"
    },
    {
        "pathogenId": 26,
        "name": "Adenovirus"
    },
    {
        "pathogenId": 27,
        "name": "Variola Virus (Smallpox Virus)"
    },
    {
        "pathogenId": 28,
        "name": "Monkeypox (MPV,MPXV, or hMPXV)"
    },
    {
        "pathogenId": 29,
        "name": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)"
    },
    {
        "pathogenId": 30,
        "name": "Ebolavirus"
    },
    {
        "pathogenId": 31,
        "name": "Dengue Virus"
    },
    {
        "pathogenId": 32,
        "name": "Adenovirus"
    },
    {
        "pathogenId": 33,
        "name": "Poliovirus"
    },
    {
        "pathogenId": 34,
        "name": "Enterovirus"
    },
    {
        "pathogenId": 35,
        "name": "Rotavirus"
    },
    {
        "pathogenId": 36,
        "name": "Bacillus anthracis"
    },
    {
        "pathogenId": 37,
        "name": "Corynebacterium diphtheriae"
    },
    {
        "pathogenId": 38,
        "name": "Mycobacterium tuberculosis"
    },
    {
        "pathogenId": 39,
        "name": "Salmonella Typhi"
    },
    {
        "pathogenId": 40,
        "name": "Vibrio cholerae"
    },
    {
        "pathogenId": 41,
        "name": "Bordetella pertussis"
    },
    {
        "pathogenId": 42,
        "name": "Haemophilus influenzae"
    },
    {
        "pathogenId": 43,
        "name": "Clostridium tetani"
    },
    {
        "pathogenId": 44,
        "name": "Plasmodium falciparum"
    },
    {
        "pathogenId": 44,
        "name": "Plasmodium falciparum"
    }
]